WHY PARTNER WITH RECARDIO

RECARDIO's therapeutic portfolio represents one of the most advanced regenerative cardiovascular platforms in clinical development today. Our lead asset, dutogliptin, is approaching Phase 3 enrollment in Acute Myocardial Infarction - and our pipeline extends into Heart Failure and additional cardiometabolic indications.

We recognize that our pipeline contains more high-value opportunities than a single company can optimally develop on its own. Accordingly, RECARDIO is actively seeking strategic partnerships with global or regional pharmaceutical and biotech organizations, who can bring complementary capabilities, commercial infrastructure, or geographic reach to accelerate delivery of these therapies to patients.